| P2093 | author name string | Jin Hyoung Kim | |
| | Jeong Hun Kim | |
| | Dong Hyun Jo | |
| P2860 | cites work | IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis | Q24320080 |
| | Complement factor H polymorphism and age-related macular degeneration | Q29614931 |
| | Oxygen sensing by HIF hydroxylases | Q29617806 |
| | Regulation of angiogenesis by hypoxia: role of the HIF system | Q29619187 |
| | Vitrectomy in the management of diabetic retinopathy | Q30740488 |
| | Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema | Q30784200 |
| | How the diabetic eye loses vision. | Q30836019 |
| | Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). | Q33231189 |
| | Age-related macular degeneration--emerging pathogenetic and therapeutic concepts | Q33263472 |
| | Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. | Q33323198 |
| | Surgical management of retinopathy of prematurity | Q33366951 |
| | Emerging treatments for retinopathy of prematurity | Q33431318 |
| | Frontiers in the management of retinoblastoma | Q33455247 |
| | N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis | Q33498560 |
| | Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization | Q33509958 |
| | Retinopathy of prematurity: current concepts in molecular pathogenesis | Q33606227 |
| | Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy | Q33703836 |
| | Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes | Q33941116 |
| | Anti-VEGF agents for age-related macular degeneration | Q34088934 |
| | Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 |
| | Update on retinoblastoma | Q34553132 |
| | Structural basis for depletion of heat shock protein 90 client proteins by deguelin. | Q34636939 |
| | Ranibizumab versus verteporfin for neovascular age-related macular degeneration. | Q34652928 |
| | The epidemiology of age-related macular degeneration | Q35688105 |
| | Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis | Q35817458 |
| | Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy | Q35886681 |
| | Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. | Q35897076 |
| | Visual experience and maturation of retinal synaptic pathways | Q35944669 |
| | Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study | Q36087887 |
| | Retinal angiogenesis in development and disease | Q36342347 |
| | Blood-neural barrier: intercellular communication at glio-vascular interface | Q36556762 |
| | Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy | Q36592901 |
| | Current understanding and management of retinopathy of prematurity | Q36792465 |
| | Vascular endothelial growth factor in eye disease | Q36929380 |
| | Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. | Q37285079 |
| | Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors | Q37477040 |
| | Emerging pharmacologic therapies for wet age-related macular degeneration | Q37558041 |
| | VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. | Q37582957 |
| | Proliferative retinopathies: angiogenesis that blinds | Q37616453 |
| | Current molecular understanding and future treatment strategies for pathologic ocular neovascularization | Q37635215 |
| | PDGF and vessel maturation | Q37662307 |
| | Current status of vascular endothelial growth factor inhibition in age-related macular degeneration | Q37704339 |
| | Effect of IL-1beta on survival and energy metabolism of R28 and RGC-5 retinal neurons | Q39911720 |
| | Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma | Q39961511 |
| | The prevalence of diabetic retinopathy among adults in the United States | Q40517905 |
| | Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. | Q43086468 |
| | Increased expression of angiogenic growth factors in age-related maculopathy | Q43095714 |
| | Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. | Q43592482 |
| | Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group | Q44012886 |
| | High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation | Q44489855 |
| | Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. | Q45887309 |
| | Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. | Q45964657 |
| | Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. | Q46294659 |
| | Pathophysiological consequences of VEGF-induced vascular permeability | Q46349878 |
| | PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema | Q46637867 |
| | Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study | Q46811103 |
| | Retinopathy of prematurity in middle-income countries | Q46826064 |
| | The blood-retinal barriers | Q48356949 |
| | Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. | Q53376059 |
| | Age-Related Macular Degeneration | Q54263427 |
| | Angiogenesis | Q56689455 |
| | Vascular endothelial growth factor Trap-Eye for diabetic macular oedema | Q62870564 |
| | Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma | Q71971584 |
| | Metabolite utilization and compartmentation in porcine carotid artery: a study using beta-guanidinopropionic acid | Q72655233 |
| | Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors | Q72752034 |
| | Diabetic retinopathy | Q75217418 |
| | Retinopathy of prematurity | Q79858093 |
| | Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab | Q81334004 |
| | Age-related macular degeneration | Q81448353 |
| | The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study | Q81920787 |
| | Off-label use of bevacizumab in retinopathy of prematurity | Q82295455 |
| | Avastin as monotherapy for retinopathy of prematurity | Q83186306 |
| | Current and future therapies for age-related macular degeneration | Q83729043 |
| | Combination therapy using the small interfering RNA bevasiranib | Q84123399 |
| | Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours | Q93921697 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| P304 | page(s) | 1557-1565 | |
| P577 | publication date | 2010-10-30 | |
| P1433 | published in | Archives of Pharmacal Research | Q13557312 |
| P1476 | title | How to overcome retinal neuropathy: the fight against angiogenesis-related blindness | |
| | How to overcome retinal neuropathy: The fight against angiogenesisrelated blindness | |
| P478 | volume | 33 | |